Sign in

Steven Eynav

Research Analyst at TD Cowen

Steven Eynav is an Analyst at TD Cowen specializing in equity research, with a focus on the biotechnology and pharmaceutical sectors. He has covered companies such as Ionis Pharmaceuticals Inc., providing targeted insights through earnings call participation and research analysis. Eynav began his equity research career prior to joining TD Cowen, and he brings a background of working with innovative healthcare firms; however, detailed performance metrics and previous firm affiliations are not publicly documented. He holds relevant FINRA securities licenses, supporting his professional credentials as a sector-focused analyst.

Steven Eynav's questions to IONIS PHARMACEUTICALS (IONS) leadership

Steven Eynav's questions to IONIS PHARMACEUTICALS (IONS) leadership • Q2 2025

Question

Steven Eynav of TD Cowen, on behalf of Yaron Werber, asked about the competitive landscape for Donadolorsen in HAE, referencing competitors like TAKHZYRO and Orlodayo, and what insights their performance offers for the upcoming launch.

Answer

CGO Kyle Jenne addressed the question, emphasizing the high rate of patient dissatisfaction with existing HAE therapies, with over 90% willing to switch for an improved option. He highlighted Donadolorsen's strong profile, including its convenient dosing interval and positive switch study data, and noted the company has hired an experienced sales team ready to compete effectively upon launch.

Ask Fintool Equity Research AI